Currently, diagnosis of AD is mainly based on positron emission tomography (PET)/CT, cognitive behavioral syndrome (CBS), and biomarkers of AD pathology (Aβ1-42/1-40, T-Tau, p-Tau) [9,57]. This evidence concerns the gene MAPT and Alzheimer disease.